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Background
Increasing the activity of defective cystic fibrosis transmembrane conductance regula-
tor (CFTR) protein is a potential treatment for cystic fibrosis.
Methods
We conducted a randomized, double-blind, placebo-controlled trial to evaluate ivacaftor 
(VX-770), a CFTR potentiator, in subjects 12 years of age or older with cystic fibrosis 
and at least one G551D-CFTR mutation. Subjects were randomly assigned to receive 
150 mg of ivacaftor every 12 hours (84 subjects, of whom 83 received at least one 
dose) or placebo (83, of whom 78 received at least one dose) for 48 weeks. The pri-
mary end point was the estimated mean change from baseline through week 24 in 
the percent of predicted forced expiratory volume in 1 second (FEV1).
Results
The change from baseline through week 24 in the percent of predicted FEV1 was greater 
by 10.6 percentage points in the ivacaftor group than in the placebo group (P<0.001). 
Effects on pulmonary function were noted by 2 weeks, and a significant treatment 
effect was maintained through week 48. Subjects receiving ivacaftor were 55% less 
likely to have a pulmonary exacerbation than were patients receiving placebo, through 
week 48 (P<0.001). In addition, through week 48, subjects in the ivacaftor group scored 
8.6 points higher than did subjects in the placebo group on the respiratory-symptoms 
domain of the Cystic Fibrosis Questionnaire–revised instrument (a 100-point scale, 
with higher numbers indicating a lower effect of symptoms on the patient’s quality 
of life) (P<0.001). By 48 weeks, patients treated with ivacaftor had gained, on average, 
2.7 kg more weight than had patients receiving placebo (P<0.001). The change from 
baseline through week 48 in the concentration of sweat chloride, a measure of CFTR 
activity, with ivacaftor as compared with placebo was −48.1 mmol per liter (P<0.001). 
The incidence of adverse events was similar with ivacaftor and placebo, with a lower 
proportion of serious adverse events with ivacaftor than with placebo (24% vs. 42%).
Conclusions
Ivacaftor was associated with improvements in lung function at 2 weeks that were 
sustained through 48 weeks. Substantial improvements were also observed in the 
risk of pulmonary exacerbations, patient-reported respiratory symptoms, weight, and 
concentration of sweat chloride. (Funded by Vertex Pharmaceuticals and others; 
VX08-770-102 ClinicalTrials.gov number, NCT00909532.)
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Cystic fibrosis, the most common le-thal genetic disease in whites, affects ap-proximately 70,000 people worldwide.1-3 
There is no cure for this disease, and the progres-
sive lung disease associated with it is the leading 
cause of death. Current treatments for cystic fibro-
sis target the secondary effects of dysfunction of 
the cystic fibrosis transmembrane conductance 
regulator (CFTR) protein.
The CFTR protein is an epithelial ion channel 
contributing to the regulation of absorption and 
secretion of salt and water in various tissues, 
including the lung, sweat glands, pancreas, and 
gastrointestinal tract.4,5 Cystic fibrosis is caused 
by mutations in CFTR that affect the quantity of 
the protein that reaches the cell surface or that 
affect the function of CFTR channels at the cell 
surface.6,7 The missense mutation G551D is the 
most prevalent example of the latter.8 Approxi-
mately 4 to 5% of patients with cystic fibrosis 
have the G551D mutation on at least one allele.1,9
Ivacaftor (VX-770) is an investigational, orally 
bioavailable agent that is designed to increase 
the time that activated CFTR channels at the cell 
surface remain open (a “potentiator”). Ivacaftor 
was shown to augment the chloride-transport ac-
tivity of G551D-CFTR protein in vitro.10 A small, 
randomized, controlled study of subjects with 
cystic fibrosis and at least one G551D-CFTR allele 
evaluated the safety profile of ivacaftor over the 
course of 14 to 28 days of treatment.11 In that study, 
ivacaftor led to significant changes from baseline 
in forced expiratory volume in 1 second (FEV1) 
and in two biomarkers of CFTR activity — sweat 
chloride and nasal potential difference — at 
several dose levels. The trial reported here was 
designed to evaluate the efficacy and safety of 
ivacaftor treatment for up to 48 weeks in sub-
jects with cystic fibrosis who had a G551D-CFTR 
mutation.
Me thods
Study Oversight
We conducted a phase 3, randomized, double-blind, 
placebo-controlled, international study of orally 
administered ivacaftor (VX-770, Vertex Pharmaceu-
ticals). The protocol, available with the full text of 
this article at NEJM.org, was reviewed and ap-
proved by the institutional review board at each 
participating center, and each subject provided 
written informed consent or written or oral as-
sent. The protocol was designed by the sponsor 
(Vertex Pharmaceuticals) in collaboration with 
the academic authors. Site investigators collected 
the data, which were analyzed by the sponsor. All 
the authors had full access to the data. The lead 
author wrote the first draft of the manuscript 
and all the authors participated in subsequent 
revisions. The first author, after consultation with 
coauthors, made the decision to submit the man-
uscript for publication. All the authors vouch for 
the accuracy and completeness of the reported 
data and for the fidelity of the study, as reported, 
to the protocol.
Study Subjects
Subjects were eligible for inclusion if they were 
12 years of age or older, had received a diagnosis 
of cystic fibrosis,12 had the G551D mutation on at 
least one CFTR allele, and had an FEV1 of 40 to 
90% of the predicted value for persons of their 
age, sex, and height.13 Subjects were randomly 
assigned, in a 1:1 ratio, to receive ivacaftor, at a 
dose of 150 mg every 12 hours, or placebo, for 
48 weeks. Throughout the study, all subjects con-
tinued to take their prestudy medications with 
the exception of hypertonic saline, which was not 
permitted, since it does not have regulatory ap-
proval in the United States as a therapy for cystic 
fibrosis. Randomization was stratified according 
to age (<18 years vs. ≥18 years) and pulmonary 
function (<70% vs. ≥70% of the predicted FEV1).
End Points
The primary efficacy end point was the absolute 
change from baseline through week 24 in the per-
cent of predicted FEV1. Secondary end points in-
cluded the change from baseline through week 48 
in the percent of predicted FEV1; the time to the 
first pulmonary exacerbation14 through week 24 
and week 48; subject-reported respiratory symp-
toms through week 24 and week 48, as assessed 
with the use of the respiratory domain of the 
Cystic Fibrosis Questionnaire–revised (CFQ-R)15 
(which is scored on a 100-point scale, with higher 
numbers indicating a lower effect of symptoms 
on the patient’s quality of life and 4 points con-
sidered to be a minimal clinically important dif-
ference); the change in weight from baseline to 
week 24 and week 48; and the change from base-
line in the concentration of sweat chloride, a mea-
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sure of CFTR channel function, through week 24 
and week 48. Tertiary efficacy end points included 
the number and duration of pulmonary exacerba-
tions, the total number of days of hospitalization for 
pulmonary exacerbations, and the need for anti-
biotic therapy for sinopulmonary signs or symp-
toms. Safety was also evaluated.
Statistical Analysis
On the basis of previous data on ivacaftor,11 we 
estimated that with a sample of at least 80 sub-
jects, the study would have 80% power to detect 
a change of 4.5 percentage points in the percent 
of predicted FEV1. All subjects who received at 
least one dose of a study drug were included in 
the analyses. The primary analysis was based on 
a mixed-effects model for repeated measures. 
The primary end point and key secondary end 
points (absolute change from baseline through 
week 24 in the score on the CFQ-R respiratory 
domain, with pooled data from the children’s 
version and the adolescent–adult version of the 
instrument; absolute change from baseline through 
week 24 in the concentration of sweat chloride; 
time to first pulmonary exacerbation through 
week 48; and absolute change in weight from 
baseline at week 48) were analyzed with the use 
of a multistage gatekeeping procedure. The change 
in FEV1 through day 15 was analyzed with the use 
of linear comparisons between the treatment 
groups at the day 15 visit. Further details of the 
methods are provided in the statistical analysis 
plan included with the protocol and in the Supple-
mentary Appendix, both of which are available 
at NEJM.org.
R esult s
Subjects
The study was conducted from June 2009 through 
January 2011. The screening, randomization, and 
follow-up of the subjects are shown in Figure 1 in 
the Supplementary Appendix. The study population 
consisted of 161 subjects who underwent ran-
domization and received at least one dose of iva-
caftor (83 subjects) or placebo (78). The mean age 
of the subjects was 25.5 years, and the mean per-
cent of predicted FEV1 was 63.6; a total of 52% of 
the subjects were women or girls (Table 1). The 
mean concentrations of sweat chloride and the 
mean weights were similar in the two groups. At 
the time of study entry, 12 subjects in the placebo 
group (15%) and 8 in the ivacaftor group (10%) 
were using inhaled hypertonic saline, which they 
discontinued before receiving the first dose of the 
study drug. Confirmatory genotyping identified 
1 subject in the placebo group who was homozy-
gous for F508del-CFTR despite a previous test indi-
cating a G551D allele. Data from this subject were 
included in the analyses.
A total of 77 subjects in the ivacaftor group 
(93%) and 68 in the placebo group (87%) com-
pleted 48 weeks of treatment. The mean rate of 
adherence to the study drug was 91% in the 
ivacaftor group and 89% in the placebo group. 
Of the 145 subjects who completed 48 weeks of 
treatment, only 1 subject (in the placebo group) 
declined to enter the open-label extension study 
(VX08-770-105).
Clinical Efficacy
Through week 24, there was an increase from base-
line of 10.4 percentage points in the percent of pre-
dicted FEV1 in the ivacaftor group, as compared 
with a decrease of 0.2 percentage points in the pla-
cebo group — a treatment effect of 10.6 percentage 
points (P<0.001) (Fig. 1A). The improvement in the 
ivacaftor group reflected a mean increase in FEV1 
of 0.367 liters, as compared with an increase of 
0.006 liters in the placebo group (treatment effect, 
0.361 liters; P<0.001) through week 24, which cor-
responded to a relative change from baseline of 
17.2% in the ivacaftor group as compared with 
0.1% in the placebo group. An effect of ivacaftor 
was noted by day 15 of treatment (treatment ef-
fect, 9.3 percentage points; P<0.001). A significant 
treatment effect was maintained throughout the 
study, with a change in the percent of predicted 
FEV1 from baseline through week 48 that was 
10.5 percentage points greater with ivacaftor than 
with placebo (P<0.001) (Table 1 in the Supple-
mentary Appendix). The distribution of individ-
ual changes from baseline through week 24 showed 
that nearly 75% of the subjects who were treated 
with ivacaftor had a mean improvement of 5 per-
centage points or more (Fig. 2 in the Supplemen-
tary Appendix). The change in the percent of pre-
dicted FEV1 was also analyzed within predefined 
subgroups, including subgroups defined accord-
ing to baseline FEV1, age, and sex. The effect of 
ivacaftor as compared with placebo was signifi-
cant in each subgroup that was analyzed (Table 2).
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At week 48, a total of 67% of subjects in the 
ivacaftor group, as compared with 41% in the 
placebo group, were free from pulmonary exac-
erbations, corresponding to a hazard ratio with 
ivacaftor of 0.455 (P = 0.001), or a 55% reduction 
in the risk of pulmonary exacerbation (Fig. 1B). 
There were 99 exacerbations (in 44 subjects) in 
the placebo group, as compared with 47 exacer-
bations (in 28 subjects) in the ivacaftor group. A 
total of 31 events (in 23 subjects) in the placebo 
group, as compared with 21 events (in 11 subjects) 
in the ivacaftor group, led to hospitalization. 
The mean (±SD) total number of days of hospital-
ization for pulmonary exacerbations per subject 
(normalized to a 48-week period) was 3.9±13.6 in 
the ivacaftor group, as compared with 4.2±8.7 in 
the placebo group (P = 0.03) (Table 2 in the Supple-
mentary Appendix).
Subjects treated with ivacaftor, as compared 
with those receiving placebo, had an improve-
Table 1. Baseline Characteristics of the Subjects.*
Characteristic
Placebo 
(N = 78)
Ivacaftor 
(N = 83)
Total 
(N = 161)
Sex — no. (%)
Male 38 (49) 39 (47) 77 (48)
Female 40 (51) 44 (53) 84 (52)
Non-Hispanic or white — no. (%)† 77 (99) 81 (98) 158 (98)
Geographic distribution — no. (%)
North America 50 (64) 50 (60) 100 (62)
Europe 19 (24) 23 (28) 42 (26)
Australia 9 (12) 10 (12) 19 (12)
Age — yr
Mean 24.7 26.2 25.5
Range 12–53 12–53 12–53
Age distribution — no. (%)
<18 yr 17 (22) 19 (23) 36 (22)
≥18 yr 61 (78) 64 (77) 125 (78)
Height — cm
Mean 166.5 167.7 167.1
Range 142.2–189.8 142.8–185.0 142.2–189.8
Weight — kg
Mean 61.2 61.7 61.5
Range 31.9–109.9 30.2–107.2 30.2–109.9
Body-mass index‡
Mean 21.9 21.7 21.8
Range 15.2–38.6 14.8–38.9 14.8–38.9
Positive for Pseudomonas aeruginosa — no. (%) 57 (73) 64 (77) 122 (76)
Non–G551D-CFTR allele — no. (%)§
Class I 11 (14) 10 (12) 21 (13)
Class II¶ 62 (79) 70 (84) 132 (82)
Class III‖ 1 (1) 0 1 (1)
Class IV 2 (3) 2 (2) 4 (2)
Class V 1 (1) 0 1 (1)
Unknown 1 (1) 1 (1) 2 (1)
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ment in scores on the CFQ-R respiratory domain 
(indicating a reduction in respiratory symptoms). 
From baseline to week 48, the scores increased 
by 5.9 points in the ivacaftor group, as compared 
with a decrease of 2.7 points in the placebo group 
(treatment effect, 8.6 points; P<0.001) (Fig. 1C). By 
week 48, subjects in the ivacaftor group had gained 
3.1 kg, as compared with a gain of 0.4 kg in the 
placebo group (treatment effect, 2.7 kg; P<0.001) 
(Fig. 1D).
CFTR Function
Through week 24, the change from baseline in 
sweat chloride was −48.7 mmol per liter in the iva-
caftor group and −0.8 mmol per liter in the place-
bo group (treatment effect, −47.9 mmol per liter; 
P<0.001) (Fig. 2A). The mean values for sweat chlo-
ride were 47.8 and 100.0 mmol per liter in the iva-
caftor and placebo groups, respectively, at week 24 
(Fig. 2B). A treatment effect was initially seen at 
day 15 and was maintained through week 48 (treat-
ment effect, −48.1; P<0.001).
Safety and Adverse-Event Profile
The incidence of adverse events through week 48 
was similar in the two groups (Table 3). As com-
pared with the placebo group, the ivacaftor group 
had a higher incidence of adverse events leading 
to interruption of the study drug (13% vs. 6%) 
(Table 3 in the Supplementary Appendix). All the 
subjects who interrupted treatment were able to 
resume taking the study drug and to complete 
the trial, with the exception of one subject in the 
placebo group who subsequently withdrew from 
the study owing to severe respiratory distress. 
Subjects in the ivacaftor group had a lower inci-
dence of adverse events leading to discontinua-
tion of the study drug (1% vs. 5%). Overall, five 
adverse events led to discontinuation: four in the 
placebo group (increased hepatic enzyme levels, 
atrioventricular block, panic attack, and respira-
tory failure) and one in the ivacaftor group (in-
creased hepatic enzyme levels). Adverse events 
occurring in at least 10% of the subjects in either 
group are shown in Table 4 in the Supplementary 
Appendix. Pulmonary exacerbation, cough, hemop-
tysis, and decreased pulmonary function occurred 
less frequently in the ivacaftor group than in the 
placebo group (≥5 percentage-point difference be-
tween the groups in incidence; minimum 10% in-
cidence in either group). Adverse events that oc-
curred more frequently in the ivacaftor group were 
headache, upper respiratory tract infection, nasal 
congestion, rash, and dizziness; none of these 
events were considered to be serious or led to 
discontinuation of the study drug.
Table 1. (Continued.)
Characteristic
Placebo
(N = 78)
Ivacaftor
(N = 83)
Total
(N = 161)
FEV1
% of predicted value
Mean 63.7 63.5 63.6
Range 31.6–97.1 37.3–98.2 31.6–98.2
Distribution — no. (%)
<70% of predicted value 45 (58) 49 (59) 94 (58)
≥70% of predicted value 33 (42) 34 (41) 67 (42)
Sweat chloride — mmol/liter
Mean 100.1 100.4 100.2
Range 58.0–121.5 74.5–128.0 58.0–128.0
* None of the characteristics differed significantly between the groups (P>0.05 for all comparisons). FEV1 denotes forced 
expiratory volume in 1 second.
† Race or ethnic group was self-reported.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ The classes of CFTR mutations are based on their molecular mechanisms in the cell, as classified by Welsh et al.16
¶ One subject in the placebo group who was homozygous for G551D-CFTR is included here.
‖ One subject in the placebo group who was homozygous for F508del-CFTR is included here.
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A total of 53 serious adverse events were re-
ported over the course of the treatment period. 
There was a lower rate of serious adverse events 
in the ivacaftor group than in the placebo group 
(24% vs. 42%). Pulmonary exacerbation and he-
moptysis occurred more frequently in the place-
bo group than in the ivacaftor group. There were 
no cases of hypoglycemia in the placebo group, 
whereas there were two cases in the ivacaftor 
group: one of the subjects had diabetes related 
to the cystic fibrosis and was receiving insulin, 
and the other had had previous episodes of symp-
toms suggestive of hypoglycemia. No deaths oc-
curred during the study. No clinically important 
trends attributable to ivacaftor were identified in 
clinical laboratory tests (serum chemical, hemato-
logic, and coagulation tests and urinalysis), vital 
signs, digital or ambulatory electrocardiograms, 
or physical examinations.
Discussion
In this randomized, placebo-controlled trial, ad-
ministration of ivacaftor, an oral CFTR potentia-
tor, was associated with significant improvements 
in primary and secondary end points in persons 
with cystic fibrosis who had at least one copy of 
the G551D-CFTR mutation. Progressive loss of lung 
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Figure 1. Changes from Baseline in Percent of Predicted FEV1, Respiratory Symptoms, and Weight, and Time to the First Pulmonary 
 Exacerbation, According to Study Group.
Panel A shows the absolute mean change from baseline in the percent of predicted forced expiratory volume in 1 second (FEV1), through 
week 48. Panel B shows the time to the first pulmonary exacerbation, expressed as estimates of the proportion of subjects free from 
events. Panel C shows the absolute mean change from baseline in the score on the respiratory domain of the Cystic Fibrosis Question-
naire–revised (CFQ-R), a quality-of-life questionnaire that is scored on a 100-point scale, with higher numbers indicating a lower effect 
of symptoms on the patient’s quality of life. The established minimum clinically important difference for the CFQ-R respiratory domain 
is 4 points. Panel D shows the absolute mean change from baseline in weight, through week 48. The values and the 95% confidence 
 intervals (indicated by I bars) in Panels A, C, and D are unadjusted. The first data points in Panels A, C, and D are baseline data.
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function is a major source of illness in patients 
with cystic fibrosis, and decreased FEV1 is associ-
ated with an increased risk of death.5 Consequently, 
FEV1 has been a key end point for the evaluation 
of new therapies for cystic fibrosis. Inhaled tobra-
mycin, as compared with placebo, was associated 
with a 12% increase in the improvement from 
baseline in FEV1 at 20 weeks17; dornase alfa, as 
compared with placebo, was associated with a 
5.8% improvement in FEV1 after 24 weeks14; and 
hypertonic saline was associated with a 3.2% im-
provement in FEV1 after 48 weeks.18 The standards 
for managing cystic fibrosis have changed con-
siderably over the past two decades.19 The subjects 
in the current study received the standard of care, 
with the exception of hypertonic saline therapy. 
In the year before the study and during the course 
of the study, subjects received dornase alfa (69%), 
oral azithromycin (63%), and inhaled tobramycin 
(39%). When added to these therapies, ivacaftor, 
as compared with placebo, was associated with a 
relative improvement of 17.2% in FEV1 over base-
line values at 24 weeks, a change that was sus-
tained to 48 weeks. Nearly 75% of the subjects 
who were treated with ivacaftor had a mean im-
provement through week 24 of 5 percentage points 
or more in the percent of predicted FEV1. The fact 
that lung function in some subjects did not ap-
pear to have a response to ivacaftor may indicate 
that other factors, such as pulmonary exacerba-
tion during the course of the study, might have 
occurred in these subjects. The subjects in the 
ivacaftor trial were slightly older than were par-
ticipants in studies of other therapies,14,16,17 but 
the severity of disease, as measured by baseline 
FEV1, was similar. Subgroup analyses were con-
ducted to ascertain whether the clinical response 
was affected by age, sex, or severity of lung dis-
ease. Although the number of subjects included 
in some of these subgroups was small, and cau-
tion is therefore advised in drawing conclusions, 
the analyses revealed consistent responses across 
subgroups.
Pulmonary exacerbations are another clini-
cally important end point, since they frequently 
lead to hospitalization, and 25% of hospitalized 
patients have permanent loss of lung function.20 
At 24 weeks, dornase alfa, as compared with pla-
cebo, reduced the risk of exacerbations by 22%.14 
At 48 weeks, hypertonic saline, as compared with 
placebo, reduced the risk by 66%.18 With the use 
of a similar definition of exacerbation, ivacaftor, 
as compared with placebo, in addition to the stan-
dard of care, resulted in a relative reduction in the 
risk of exacerbation of 60% at 24 weeks and 55% 
at 48 weeks. Treatment with ivacaftor also reduced 
the number of days of hospitalization, the total 
number and duration of exacerbations, and the 
number of pulmonary exacerbations requiring 
intravenous antibiotics. The within-group change 
in the score on the CFQ-R respiratory domain 
through 48 weeks exceeded the minimal clini-
cally important difference of 4 points established 
for this domain in patients with stable disease.21
Patients with cystic fibrosis typically have dif-
ficulty gaining and maintaining weight.1 Weight 
gain was measured in two studies of oral azithro-
mycin.22,23 In those trials, the mean treatment ef-
fect with azithromycin as compared with placebo 
during the 24-week treatment period was a weight 
gain of 0.7 kg in subjects with endobronchial colo-
nization with Pseudomonas aeruginosa22 and 0.58 kg 
in subjects without P. aeruginosa endobronchial 
colonization,23 and these treatment effects were 
associated with improved pulmonary status in the 
subjects receiving azithromycin. In the current 
study, the weight gain at 48 weeks was 3.1 kg in 
subjects receiving ivacaftor, as compared with 
Table 2. Treatment Effect of Ivacaftor with Respect 
to the Change from Baseline through Week 48 in the 
Percent of Predicted FEV1, According to Subgroups.*
Subgroup Treatment Effect P Value
Baseline % of predicted FEV1
<70% 10.6 <0.001
≥70% 10.3 <0.001
Geographic region
North America 9.0 <0.001
Europe 9.9 <0.001
Australia 11.9 0.008
Sex
Male 11.0 <0.001
Female 11.6 <0.001
Age
<18 yr 11.4 0.005
≥18 yr 9.9 <0.001
* The treatment effect represents the difference between the 
ivacaftor group and the placebo group with respect to  
the absolute change from baseline through week 48  
in the percent of predicted FEV1.
The New England Journal of Medicine 
Downloaded from nejm.org at QUEENS UNIV MED LIB on October 2, 2012. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 365;18 nejm.org november 3, 20111670
0.4 kg in subjects receiving placebo, with a 
similar between-group difference at 24 weeks. 
In patients with cystic fibrosis, weight is affect-
ed by multiple factors, including pancreatic in-
sufficiency with maldigestion, increased caloric 
needs, diabetes, and anorexia.5,24 A systemic CFTR 
modulator, such as ivacaftor, may also affect CFTR 
function in gastrointestinal epithelia, which may 
contribute to improved absorption of nutrients 
in patients with cystic fibrosis; however, no caus-
al relationship was studied or proven in this 
trial.
CFTR plays an important role in the reabsorp-
tion of chloride in the sweat duct.25 We observed 
a large correction of elevated levels of sweat chlo-
ride in the ivacaftor group, as compared with the 
placebo group, as early as 2 weeks after the ini-
tiation of the study drug. Ivacaftor is the first 
agent to show a reduction in the sweat chloride 
level to values below the diagnostic threshold for 
cystic fibrosis (60 mmol per liter). This finding 
confirms the observation from an early-phase 
trial that ivacaftor improved CFTR-mediated ion-
transport function.11
The mechanisms by which changes in CFTR 
function may lead to pulmonary and weight 
changes are incompletely understood and prob-
ably multifactorial. In vitro studies of air–liquid 
interface cultures of bronchial epithelial cells from 
the lungs of patients with cystic fibrosis have 
shown that correction of abnormal CFTR-mediated 
ion transport increases the air–surface fluid level 
and ciliary beat frequency.10 Thus, the improvement 
in FEV1 observed after 2 weeks in the current 
study may reflect improved airway clearance. The 
limited additional improvements in FEV1 through 
48 weeks suggest that continued longitudinal data 
will be required to assess whether CFTR modu-
lation can effect further physiological changes 
in the airways of patients with cystic fibrosis. 
Weight gain appeared to plateau after 16 weeks. 
This may indicate either that subjects reached 
their ideal body weight or that other physiologi-
cal factors prevented them from gaining addi-
Table 3. Adverse Events.
Adverse Event
Placebo
(N = 78)
Ivacaftor
(N = 83)
no. of subjects (%)
Any adverse event 78 (100) 82 (99)
Serious adverse event* 33 (42) 20 (24)
Pulmonary exacerbation 26 (33) 11 (13)
Hemoptysis 4 (5) 1 (1)
Hypoglycemia 0 2 (2)
Adverse event leading to study-
drug interruption
5 (6) 11 (13)
Adverse event leading to study-
drug discontinuation
4 (5) 1 (1)
* Included are serious adverse events that occurred in 
more than one subject per group.
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Figure 2. Changes from Baseline through Week 48 in Sweat Chloride, 
 According to Study Group.
Panel A shows the mean change from baseline in the concentration of 
sweat chloride. Panel B shows the actual mean concentrations of sweat 
chloride over time; the dashed line at 60 mmol per liter represents the cut-
off point for the diagnosis of cystic fibrosis. The values and 95% confi-
dence intervals (indicated by I bars) in both panels are unadjusted. The 
first data points in both panels are baseline data.
The New England Journal of Medicine 
Downloaded from nejm.org at QUEENS UNIV MED LIB on October 2, 2012. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
A CFTR Potentiator for Cystic Fibrosis
n engl j med 365;18 nejm.org november 3, 2011 1671
tional weight. The longer-term effects of modu-
lation of CFTR on lung function will be monitored 
in the participants receiving ivacaftor in the on-
going open-label follow-up study. Although the 
complete chain of events from CFTR dysfunction 
to ion-transport imbalance to progressive obstruc-
tive and destructive airway disease is still unknown, 
this study suggests that a drug targeting CFTR 
dysfunction can affect lung function and symp-
toms, thus confirming that CFTR is a valid thera-
peutic target and providing an important tool 
for further study of the pathophysiology of cystic 
fibrosis.
Daily oral administration of ivacaftor for 
48 weeks was not associated with a greater safety 
risk than that observed with placebo. Serious ad-
verse events were less common in the ivacaftor 
group, primarily owing to a reduced incidence of 
pulmonary exacerbations and hemoptysis. The fre-
quency of liver enzyme levels that were more than 
2 times the upper limit of the normal range for 
age was similar in the ivacaftor and placebo 
groups (Table 5 in the Supplementary Appendix) 
and was also similar to the frequency in adult 
and adolescent populations with cystic fibrosis.26
In summary, these findings represent an im-
portant milestone in the development of treat-
ments designed to improve CFTR protein function 
as a means of addressing the underlying cause of 
cystic fibrosis and begin to fulfill the promise 
ushered in with the discovery of the CFTR gene.
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